BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amarna Therapeutics B.V. And TNO Announce SVac Research And Development Partnership


6/10/2009 12:25:41 PM

Leiden, The Netherlands, June 09, 2009 / b3c newswire / - Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna’s viral gene delivery platform SVac. Under this agreement, TNO will develop novel methods for the manufacture, formulation and testing of viral gene delivery systems such as the SVac platform of Amarna. The collaboration is partly supported by a co-financing initiative aimed at developing innovative technologies.

“We are very pleased to work with TNO”, said Ben van Leent, CEO of Amarna Therapeutics. “We have developed a revolutionary novel viral gene delivery vector platform technology SVac for producing human therapeutics that have the potential to save lives and improve the quality of life for millions of people worldwide that are suffering from life-threatening or severe chronic diseases. The technology is now available to address the major diseases of our time including genetic disorders, autoimmune diseases, allergies and cancer. Amarna Therapeutics acts at the forefront of the therapeutic vaccination and gene therapy markets. Both markets are rapidly growing to reach an estimated 40 billion Euro’s in 2015. I’m convinced that the therapeutics in our pipeline all have blockbuster potential. The partnership with TNO enables us to initiate the first time in man clinical trials with one of our lead therapeutics in 2010.”

“The partnership between TNO and Amarna allows us to expand our pre-clinical development services into the extremely important therapeutic area of viral vector and gene delivery technologies and is yet another important step in our establishment of a fully integrated and highly innovative package of biopharmaceutical development capabilities” says Menzo Havenga, Managing Director of Biosciences at TNO.

About Amarna Therapeutics - www.amarnatherapeutics.com

Amarna Therapeutics B.V. is a Biotechnology company that develops therapeutic vaccinations to treat immunity-associated diseases including autoimmune diseases, allergies and cancer and gene therapies to treat genetic disorders. The base of Amarna’s therapeutics is the SVac viral gene delivery vector platform, which provides sensational characters unheard of in the Pharma arena, creating opportunities to serve markets with enormous potential due to clinical unmet needs.

About SVac - http://www.amarnatherapeutics.com/cms/page/show/2/

Our SVac viral gene delivery vector platform has a number of unique properties compared to other viral gene delivery vectors such as lentiviral, poxviral, alphaviral, adenoviral and adeno-associated virus (AAV) vector systems. SVac is non-immunogenic in humans, highly stable, safe to use and can be cost effectively produced in large amounts in a proprietary producer cell line denoted SuperVero. Moreover, the vector has extensively been tested for safety in model animals. The SuperVero cell line has been qualified and tested using Quality Control (QC) assays and its use for manufacturing clinical trial material has been validated. The whole vector production process is similar to the current manufacturing processes of the polio, rabies and influenza virus vaccines in which a master seed virus is seeded to producer cells in large fermentors. Because of its immunological inertia in man SVac is the only vector system known that is suitable for for treating genetic disorders and immunity associated diseases.

About TNO - www.tno.nl/pharma

TNO is a prominent, independent knowledge company whose expertise and research contribute significantly to the competitiveness of businesses and organizations, to the economy and to the quality of life as a whole. Its versatility and capacity to integrate a broad diversity of sciences and technologies makes TNO unique. TNO employs about 4300 professionals in five core areas: TNO Quality of Life, TNO Defense, Security and Safety, TNO Science and Industry, TNO Built Environment and Geosciences, TNO Information and Communication Technology.

Within biopharmaceutical development, TNO’s mission is to optimize and accelerate the transition of human therapeutics from discovery to the clinic. TNO strives towards this goal by establishing innovative product development and manufacturing technologies and applying them in a fully integrated package of pre-clinical development services.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES